EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

CAF-mediated compartmentalized dual POSTN–ITGB8 axis drives Osimertinib resistance in lung adenocarcinoma

Jiaming Cao, Yibing Liu, Junting Chen, Xuelian Li, Zhihua Yin, Xiaoxia Xue, Bonan Chen, Baosen Zhou, Chang Zheng

Journal of Pharmaceutical Analysis · 2026-06 · 101689

DOI: 10.1016/j.jpha.2026.101689 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Pharmaceutical Analysis, 2026-06. Verfasst von Jiaming Cao und 8 weiteren Autor:innen. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Cao, J., Liu, Y., Chen, J., Li, X., Yin, Z., Xue, X., Chen, B., Zhou, B., & Zheng, C. (2026). CAF-mediated compartmentalized dual POSTN–ITGB8 axis drives Osimertinib resistance in lung adenocarcinoma. Journal of Pharmaceutical Analysis, 101689. https://doi.org/10.1016/j.jpha.2026.101689

Vancouver

Cao J, Liu Y, Chen J, Li X, Yin Z, Xue X, et al. CAF-mediated compartmentalized dual POSTN–ITGB8 axis drives Osimertinib resistance in lung adenocarcinoma. Journal of Pharmaceutical Analysis. 2026:101689. doi:10.1016/j.jpha.2026.101689

BibTeX
@article{Cao2026,
  author = {Cao, Jiaming and Liu, Yibing and Chen, Junting and Li, Xuelian and Yin, Zhihua and Xue, Xiaoxia and Chen, Bonan and Zhou, Baosen and Zheng, Chang},
  title = {CAF-mediated compartmentalized dual POSTN–ITGB8 axis drives Osimertinib resistance in lung adenocarcinoma},
  journal = {Journal of Pharmaceutical Analysis},
  year = {2026},
  pages = {101689},
  doi = {10.1016/j.jpha.2026.101689}
}
Kostenlos starten →